FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894101204> ?p ?o ?g. }

• W2894101204 endingPage "155" @default.
• W2894101204 startingPage "145" @default.
• W2894101204 abstract "Purpose To assess the hypothesis that fluorometholone 0.1% eye drops are safe and effective as adjunctive therapy for trachomatous trichiasis (TT) surgery; determining the most promising dose. Design Randomized, placebo-controlled, double-masked parallel dose–ranging clinical trial. Methods Patients undergoing upper lid TT surgery at a rural Ethiopian hospital were randomized to fluorometholone 0.1% twice daily for 4 weeks, 4 times daily for 4 weeks, 4 times daily for 8 weeks, or matching frequency placebo in a 3:1:3:1:3:1 ratio for 1 eye. Randomization was stratified by TT severity (1-4 vs ≥5 lashes touching the globe). Safety outcomes (intraocular pressure [IOP] elevation, cataract, and other dose-limiting toxicities) and postoperative TT incidence were assessed over 1 year. Results Subjects randomized were 39:13:39:13:38:13 in the respective groups, and 1 subject in the 8-weeks fluorometholone group was withdrawn. Of 154 subjects, 148 (96.1%) completed 1 year's follow-up. Among 76 eyes receiving fluorometholone 4 times daily, 1 developed IOP elevation ≥ 30 mm Hg (to 37 mm Hg) and 1 had an allergic reaction attributed to the study drug; each resolved upon drug cessation without sequelae. No cataract or other dose-limiting toxicity events occurred. Postoperative TT within 1 year occurred in 29.3% of placebo eyes vs 17.7%, 19.6%, and 23.2% among the respective fluorometholone groups (P = .29 comparing placebo vs all active treatments combined). Conclusions The results suggest fluorometholone 0.1% is likely to be safe and efficacious to reduce postoperative TT following TT surgery, and 1 drop twice daily for 4 weeks is the most promising dose. Confirmation in a full-scale clinical trial is needed before programmatic implementation. To assess the hypothesis that fluorometholone 0.1% eye drops are safe and effective as adjunctive therapy for trachomatous trichiasis (TT) surgery; determining the most promising dose. Randomized, placebo-controlled, double-masked parallel dose–ranging clinical trial. Patients undergoing upper lid TT surgery at a rural Ethiopian hospital were randomized to fluorometholone 0.1% twice daily for 4 weeks, 4 times daily for 4 weeks, 4 times daily for 8 weeks, or matching frequency placebo in a 3:1:3:1:3:1 ratio for 1 eye. Randomization was stratified by TT severity (1-4 vs ≥5 lashes touching the globe). Safety outcomes (intraocular pressure [IOP] elevation, cataract, and other dose-limiting toxicities) and postoperative TT incidence were assessed over 1 year. Subjects randomized were 39:13:39:13:38:13 in the respective groups, and 1 subject in the 8-weeks fluorometholone group was withdrawn. Of 154 subjects, 148 (96.1%) completed 1 year's follow-up. Among 76 eyes receiving fluorometholone 4 times daily, 1 developed IOP elevation ≥ 30 mm Hg (to 37 mm Hg) and 1 had an allergic reaction attributed to the study drug; each resolved upon drug cessation without sequelae. No cataract or other dose-limiting toxicity events occurred. Postoperative TT within 1 year occurred in 29.3% of placebo eyes vs 17.7%, 19.6%, and 23.2% among the respective fluorometholone groups (P = .29 comparing placebo vs all active treatments combined). The results suggest fluorometholone 0.1% is likely to be safe and efficacious to reduce postoperative TT following TT surgery, and 1 drop twice daily for 4 weeks is the most promising dose. Confirmation in a full-scale clinical trial is needed before programmatic implementation." @default.
• W2894101204 created "2018-10-05" @default.
• W2894101204 creator A5003914593 @default.
• W2894101204 creator A5006274430 @default.
• W2894101204 creator A5025364864 @default.
• W2894101204 creator A5026907315 @default.
• W2894101204 creator A5031739654 @default.
• W2894101204 creator A5043549024 @default.
• W2894101204 creator A5061428301 @default.
• W2894101204 creator A5086915661 @default.
• W2894101204 date "2019-01-01" @default.
• W2894101204 modified "2023-10-09" @default.
• W2894101204 title "Fluorometholone 0.1% as Ancillary Therapy for Trachomatous Trichiasis Surgery: Randomized Clinical Trial" @default.
• W2894101204 cites W1971671555 @default.
• W2894101204 cites W1971834439 @default.
• W2894101204 cites W1973137360 @default.
• W2894101204 cites W1976708963 @default.
• W2894101204 cites W2050512279 @default.
• W2894101204 cites W2060502171 @default.
• W2894101204 cites W2084062501 @default.
• W2894101204 cites W2091987769 @default.
• W2894101204 cites W2096963032 @default.
• W2894101204 cites W2099838434 @default.
• W2894101204 cites W2116773235 @default.
• W2894101204 cites W2123687909 @default.
• W2894101204 cites W2136775845 @default.
• W2894101204 cites W2146418270 @default.
• W2894101204 cites W2149725471 @default.
• W2894101204 cites W2234203740 @default.
• W2894101204 cites W2492892285 @default.
• W2894101204 cites W2761604622 @default.
• W2894101204 cites W2797864828 @default.
• W2894101204 cites W324911061 @default.
• W2894101204 cites W4211108838 @default.
• W2894101204 doi "https://doi.org/10.1016/j.ajo.2018.09.017" @default.
• W2894101204 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7453666" @default.
• W2894101204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30267699" @default.
• W2894101204 hasPublicationYear "2019" @default.
• W2894101204 type Work @default.
• W2894101204 sameAs 2894101204 @default.
• W2894101204 citedByCount "3" @default.
• W2894101204 countsByYear W28941012042019 @default.
• W2894101204 countsByYear W28941012042023 @default.
• W2894101204 crossrefType "journal-article" @default.
• W2894101204 hasAuthorship W2894101204A5003914593 @default.
• W2894101204 hasAuthorship W2894101204A5006274430 @default.
• W2894101204 hasAuthorship W2894101204A5025364864 @default.
• W2894101204 hasAuthorship W2894101204A5026907315 @default.
• W2894101204 hasAuthorship W2894101204A5031739654 @default.
• W2894101204 hasAuthorship W2894101204A5043549024 @default.
• W2894101204 hasAuthorship W2894101204A5061428301 @default.
• W2894101204 hasAuthorship W2894101204A5086915661 @default.
• W2894101204 hasBestOaLocation W28941012042 @default.
• W2894101204 hasConcept C118487528 @default.
• W2894101204 hasConcept C120665830 @default.
• W2894101204 hasConcept C121332964 @default.
• W2894101204 hasConcept C126322002 @default.
• W2894101204 hasConcept C141071460 @default.
• W2894101204 hasConcept C142724271 @default.
• W2894101204 hasConcept C168563851 @default.
• W2894101204 hasConcept C204243189 @default.
• W2894101204 hasConcept C204787440 @default.
• W2894101204 hasConcept C27081682 @default.
• W2894101204 hasConcept C2778527774 @default.
• W2894101204 hasConcept C2779578545 @default.
• W2894101204 hasConcept C2781019283 @default.
• W2894101204 hasConcept C2781092963 @default.
• W2894101204 hasConcept C2781302119 @default.
• W2894101204 hasConcept C42219234 @default.
• W2894101204 hasConcept C535046627 @default.
• W2894101204 hasConcept C61511704 @default.
• W2894101204 hasConcept C71924100 @default.
• W2894101204 hasConceptScore W2894101204C118487528 @default.
• W2894101204 hasConceptScore W2894101204C120665830 @default.
• W2894101204 hasConceptScore W2894101204C121332964 @default.
• W2894101204 hasConceptScore W2894101204C126322002 @default.
• W2894101204 hasConceptScore W2894101204C141071460 @default.
• W2894101204 hasConceptScore W2894101204C142724271 @default.
• W2894101204 hasConceptScore W2894101204C168563851 @default.
• W2894101204 hasConceptScore W2894101204C204243189 @default.
• W2894101204 hasConceptScore W2894101204C204787440 @default.
• W2894101204 hasConceptScore W2894101204C27081682 @default.
• W2894101204 hasConceptScore W2894101204C2778527774 @default.
• W2894101204 hasConceptScore W2894101204C2779578545 @default.
• W2894101204 hasConceptScore W2894101204C2781019283 @default.
• W2894101204 hasConceptScore W2894101204C2781092963 @default.
• W2894101204 hasConceptScore W2894101204C2781302119 @default.
• W2894101204 hasConceptScore W2894101204C42219234 @default.
• W2894101204 hasConceptScore W2894101204C535046627 @default.
• W2894101204 hasConceptScore W2894101204C61511704 @default.
• W2894101204 hasConceptScore W2894101204C71924100 @default.
• W2894101204 hasFunder F4320306811 @default.
• W2894101204 hasFunder F4320309370 @default.
• W2894101204 hasLocation W28941012041 @default.
• W2894101204 hasLocation W28941012042 @default.
• W2894101204 hasOpenAccess W2894101204 @default.
• W2894101204 hasPrimaryLocation W28941012041 @default.
• W2894101204 hasRelatedWork W1971230047 @default.

• next